Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Gold Trust (IAU) vs Viatris Inc (VTRS) Price & Performance

iShares Gold TrustTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

iShares Gold Trust vs Viatris Inc — how do they compare? iShares Gold Trust trades at $76.32, while Viatris Inc trades at $17 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while iShares Gold Trust pays none, and Viatris Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.

IAUVTRS
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$101.57$17.39
52-Week Low
$61.62$8.74
Market Cap
$19.79B
Enterprise Value
$32.00B
Dividend Yield
2.83%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Gold Trust

IAU, the iShares Gold Trust ETF, trades at $75.35, down 0.2% on the day. Technical indicators are bearish, with moving averages signaling a downtrend and key support at $75. Recent news highlights institutional activity, including a new position by Eurizon Asset Management Hungary Ltd. in Q1 2026, while broader gold sentiment is pressured by expectations of sustained higher interest rates.

The outlook for IAU is influenced by macroeconomic factors affecting gold. Higher-for-longer interest rate expectations from the Fed (WSJ, 2026-07-19) pose a headwind, but structural central bank buying (WSJ, 2026-07-16) offers support. The primary risk is gold's sensitivity to monetary policy, while the opportunity lies in its role as a hedge amid economic uncertainty.

Viatris Inc

Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.

Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Gold Trust

IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.

Read more on IAU

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS